United Microelectronics Corp vs GeneDx Holdings Corp — how do they compare? United Microelectronics Corp trades at $22.92 (market cap $58.02B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: United Microelectronics Corp is far larger — about 28.7× GeneDx Holdings Corp's market cap, and United Microelectronics Corp pays a 1.76% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold United Microelectronics Corp for 42 Days and GeneDx Holdings Corp for 19 Days on average.
| UMC | WGS | |
|---|---|---|
Market Cap | $58.02B | $2.02B |
Volume | 11,897,809 | 734,640 |
Sector | Technology | Health |
52-Week High | $28.02 | $167.51 |
52-Week Low | $7.02 | $34.51 |
Typical Hold Time | 42 Days | 19 Days |
Enterprise Value | $55.10B | $2.05B |
Dividend Yield | 1.76% | — |
Signals from Pluang's Aura AI — not financial advice
UMC trades at $22.92, down 1.67% on the day, with a bullish technical signal despite recent weakness. The company has delivered strong earnings beats in recent quarters, with Q2 2026 EPS of $0.54 significantly exceeding the $0.16 estimate. Revenue is projected to grow to $250.7 billion in 2026, with net income margin improving to 32.75%. Cash flow trends show a positive turnaround with 2025 net cash flow of $5.66 billion after two years of negative flows.
The outlook remains positive with strong profitability metrics and analyst upgrades, though competition and market volatility present risks. The stock appears fundamentally sound with improving cash generation and earnings momentum, supported by AI-driven semiconductor demand. Valuation metrics suggest reasonable pricing relative to growth prospects.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →